Last updated: July 12, 2026
ABRAXIS BIOSCIENCE, LLC v. QILU PHARMACEUTICAL (HAINAN) CO., LTD. (1:26-cv-00140): Litigation Summary, Claims at Issue, and Risk for Biosimilar/Generic Entry
Summary: Litigation ABRAXIS BIOSCIENCE, LLC v. QILU PHARMACEUTICAL (HAINAN) CO., LTD., 1:26-cv-00140 is newly filed (case number indicates 2026). The docket-level and filing-level information required to produce a complete, accurate claims-and-legal-basis analysis (asserted patents, NDA/BLA/ANDA reference product, Paragraph IV status, venue-specific procedural posture, and the precise causes of action and remedies pleaded) is not present in the provided input.
Result: No complete and accurate litigation summary or patent-estate analysis can be generated from the case caption and docket number alone.
What claims are at issue in ABRAXIS BIOSCIENCE v. QILU PHARMACEUTICAL (HAINAN) (1:26-cv-00140)?
A litigation summary depends on the complaint’s pleaded facts and the patent list asserted. Those elements are not included in the provided information.
Which patents are asserted in this case?
Not provided.
Is the case an ANDA Paragraph IV, 505(b)(2) dispute, or BLA/Biosimilar action?
Not provided.
What product and reference biologic or drug are implicated?
Not provided.
When was ABRAXIS BIOSCIENCE v. QILU PHARMACEUTICAL (HAINAN) filed, and what is the current procedural posture?
The input includes only the docket number and parties’ names.
Filing date, assigned judge, and court
Not provided.
Motions filed (TRO/preliminary injunction, motion to dismiss, claim construction, stay)
Not provided.
Scheduling order and key upcoming deadlines
Not provided.
How does patent expiration timing affect the litigation strategy in ABRAXIS v. QILU?
A timing analysis requires:
- the asserted patent numbers,
- their expiration dates and any listed regulatory exclusivities,
- whether the claims are composition-of-matter, method-of-use, formulation, or manufacturing-process,
- and any stay or phase-in mechanics tied to Hatch-Waxman.
None of that is available from the provided input.
Which patent expirations drive settlement leverage?
Not provided.
Does regulatory exclusivity (e.g., BLA exclusivity, orphan drug, pediatric exclusivity) extend the launch risk window?
Not provided.
What is the Orange Book status of the referenced product in ABRAXIS v. QILU?
Orange Book status is patent-by-patent and formulation-specific and must be pulled from FDA listings for the implicated NDA/ANDA.
Not provided.
Are there biosimilar or interchangeability risk factors tied to QILU’s planned product in ABRAXIS v. QILU?
Biosimilar or interchangeability risk requires identification of:
- the proposed biosimilar’s reference product,
- whether 351(k) is involved,
- whether a BLA is approved, pending, or withdrawn,
- and the asserted patents tied to biosimilar-specific statutory mechanics.
Not provided.
Which Paragraph IV or 351(k) theories are being used in the ABRAXIS complaint?
A credible theory analysis requires the complaint’s legal counts, the Markman issues, and the infringement/noninfringement/invalidity positions.
Not provided.
How strong is the patent estate asserted by ABRAXIS in this case?
Strength assessment requires:
- asserted claim scopes,
- prosecution history and claim construction anchors,
- prior art and obviousness/collateral estoppel positions,
- and any known enforcement history.
Not provided.
What settlements or consent judgments are typical for a case like ABRAXIS v. QILU?
Settlement patterns depend on:
- early injunction posture,
- whether there are parallel ITC actions,
- and the specific patent claims and remaining life.
Not provided.
Which generic or biosimilar entry risks exist for QILU depending on outcome in ABRAXIS v. QILU?
Entry risk depends on:
- remaining patent and exclusivity,
- whether the case results in a 30-month stay,
- and whether the launch is blocked by injunction, carve-outs, or design-around.
Not provided.
Key Takeaways
- The case caption and docket number are insufficient to produce an accurate litigation summary, patent-assertion mapping, or exclusivity/patent-expiration risk analysis.
- A defensible analysis requires docket-level details (complaint counts, asserted patents, referenced FDA application, and procedural milestones). Those are not present in the provided input.
FAQs
- What patents does ABRAXIS assert in 1:26-cv-00140?
- Is the action tied to an ANDA Paragraph IV or an FDA 351(k) pathway?
- What is the current motion posture in ABRAXIS Bioscience v. QILU Pharmaceutical (Hainan) Co., Ltd.?
- Which FDA reference product is implicated, and what is its Orange Book/Biosimilar patent listing status?
- What injunction or damages remedies does ABRAXIS seek in this case?
References
No sources were provided in the prompt, and no docket documents or FDA patent listings were included to cite.
